Prospective International Multi-center Clinical Trial of PGT-A Upgrade
Condition(s) studied
Investigational drug(s) / intervention(s)
PGT-A upgrade: A comprehensive PGT solution capable of simultaneously detecting embryonic chromosomal aneuploidy, mosaicism, microdeletions/ microduplications, heteroploidy, and LOH in a single assay.
Study summary
The goals of this international multicenter cross-sectional study are:
1. To provide patients with a comprehensive PGT solution capable of simultaneously detecting embryonic chromosomal aneuploidy, mosaicism, microdeletions/ microduplications, heteroploidy, and heterozygosity (LOH) in a single assay, thereby reducing miscarriage and birth defects;
2. To perform PGT analysis on abnormally fertilized embryos, select euploid embryos with normal ploidy, and calculate embryo utilization rates;
3. To reduce the false-positive rate through confirmation of mosaic embryos and subsequent analysis of its origin, thereby minimizing embryo wastage;
4. To provide molecular genetic evidence for expert consensus on clinical management of atypically fertilized embryos, of pathogenic/likely pathogenic small CNVs, optimize mosaic embryo transfer strategies, and inform preconception intervention;
5. To enhance international PGT testing standards through international multi-center collaboration.
The study will enroll patients undergoing PGT-A from seven domestic and international centers, with patient enrollment expected to be completed within one year. PGT-A upgrade testing will be performed on embryos from enrolled patients, and the incidence rates of Incidence of microdeletions/microduplications, heteroploidy, LOH will be statistically analyzed. All patients who undergo embryo transfer will be followed up for clinical outcomes and birth defects.
Eligibility
Primary outcome measure(s)
- Incidence of microdeletions/microduplications — Two months after oocyte retrieval
Trophectoderm biopsy samples undergo whole genome amplification followed by NGS. Microdeletions and microduplications are identified according to Human Genome Assembly GRCh19 (hg19) or updated versions. The incidence will be calculated as the number of embryos with pathogenic or likely pathogenic microdeletions/microduplications (1-4M) divided by the total number of embryos. - Incidence of heteroploidy — Two months after oocyte retrieval
Trophectoderm biopsy samples undergo whole genome amplification followed by NGS. Heteroploidy is identified according to Human Genome Assembly GRCh19 (hg19) or updated versions. The incidence will be calculated as the number of embryos with heteroploidy divided by the total number of embryos. - Incidence of loss of heterozygosity — Two months after oocyte retrieval
Trophectoderm biopsy samples underwent whole genome amplification followed by NGS. Loss of heterozygosity were identified according to Human Genome Assembly GRCh19 (hg19) or updated versions. The incidence will be calculated as the number of embryos with loss of heterozygosity divided by the total number of embryos
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| Biocódices | Buenos Aires | Argentina | |
| CITIC-Xiangya Reproductive & Genetic Hospital | Changsha | Hunan | |
| Nanjing Women and Children's Healthcare Hospital | Nanjing | Jiangsu | |
| First People's Hospital of Yunnan Province | Kunming | Yunnan | |
| Thomson Hospital | Petaling Jaya | Malaysia | |
| Miracle | Daegu | South Korea | |
| Institute Bernabéu | Alicante | Spain |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07533630 on ClinicalTrials.gov ↗ ← All trials in South Korea